How HLA genetics affects the immune system's ability to detect tumors
HLA genetics shapes tumor immunosurveillance
This study is looking at how certain genes related to the immune system might help the body fight lung cancer, especially in smokers, using mice to learn more about how these genes work and how they could lead to better cancer treatments.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11068006 on NIH RePORTER |
What this research studies
This research investigates the role of HLA genetics in the immune system's ability to recognize and respond to tumors, particularly focusing on lung cancer. By using a mouse model, the study aims to understand how variations in HLA genes influence tumor development and the immune response. The researchers will explore the mechanisms by which HLA heterozygosity may provide protection against cancer, particularly in smokers. This work could lead to new insights into how the immune system can be harnessed for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a genetic predisposition to lung cancer, particularly smokers or those with a family history of the disease.
Not a fit: Patients with cancers unrelated to HLA genetics or those who do not have a genetic predisposition to lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapies that better utilize the body's immune system to fight tumors.
How similar studies have performed: Previous research has shown promising results in understanding the role of HLA genetics in cancer immunity, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Olumuyide, Ezekiel Olufikayomi — Icahn School of Medicine at Mount Sinai
- Study coordinator: Olumuyide, Ezekiel Olufikayomi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.